This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher (DHR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed at $306.38 in the latest trading session, marking a +0.34% move from the prior day.
Carlisle (CSL) Gains From Solid Demand and Buyout Synergies
by Zacks Equity Research
Carlisle (CSL) seems a good investment option. It boasts healthy product demand, synergistic gains from buyouts, solid product offerings and a focus on product introductions.
Danaher (DHR) Q4 Sales to Exceed Guidance on Healthy Demand
by Zacks Equity Research
Danaher (DHR) communicates that its fourth-quarter 2021 sales performance is better than previously expected as solid demand in all three segments drives the performance.
Griffon (GFF) Highlights Importance of Hunter Fan Acquisition
by Zacks Equity Research
Griffon (GFF) reveals the pros of the proposed acquisition of Hunter Fan to shareholders. Hunter Fan's product offerings, customer base, and innovation abilities will likely boost Griffon's earnings.
ITT to Gain From Business Strength & Investments Amid Risks
by Zacks Equity Research
ITT stands to gain from strength in businesses, innovation investments and shareholder-friendly policies. Costs and expenses and capital expenditure witness a rise.
Danaher (DHR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $303.92, marking a -0.45% move from the previous day.
3M (MMM) to Gain From End-Market Strength, Risks Persist
by Zacks Equity Research
3M (MMM) is poised to benefit from strength in its end markets, solid portfolio of products, and shareholder-friendly policies. Pandemic-related uncertainties and a high debt level pose concerns.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $329.01, moving +0.16% from the previous trading session.
Here's Why Danaher (DHR) Is a Worthy Investment Pick for 2022
by Zacks Equity Research
Danaher (DHR) seems a good pick for 2022. It boasts segmental opportunities, buyout-led gains, solid product offerings and a focus on innovation. Rewards to shareholders add to its attractiveness.
5 S&P 500 Stocks That Helped the Index Score Big in 2021
by Avisekh Bhattacharjee
NVIDIA (NVDA), Danaher (DHR), Rockwell (ROK), Gartner (IT) and Ingersoll Rand (IR) are some of the top S&P 500 stocks that outperformed the index in 2021.
Danaher (DHR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $326.58, moving +0.97% from the previous trading session.
Danaher (DHR) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $320.79, marking a +0.35% move from the previous day.
Danaher (DHR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $319.68, marking a +1.83% move from the previous day.
General Electric (GE) Acquires BK Medical, To Buy Opus One
by Zacks Equity Research
General Electric's (GE) BK Medical acquisition is expected to boost its offerings in the ultrasound space. Also, Opus One, when acquired, will add vigor to GE Digital offerings to electric utilities.
3 Reasons Growth Investors Will Love Danaher (DHR)
by Zacks Equity Research
Danaher (DHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Crane (CR) Stock Outpacing Its Conglomerates Peers This Year?
by Zacks Equity Research
Here is how Crane (CR) and Danaher (DHR) have performed compared to their sector so far this year.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $318.49, moving +1.11% from the previous trading session.
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
BRRAY vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
BRRAY vs. DHR: Which Stock Is the Better Value Option?
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Honeywell (HON) to Buy US Digital Designs, To Aid Public Safety
by Zacks Equity Research
Honeywell's (HON) US Digital Designs acquisition is expected to boost its offerings for improving public safety communications. US Digital Designs will be part of the Building Technologies segment.
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $319.28, moving +0.32% from the previous trading session.
Danaher (DHR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Danaher (DHR) closed at $312.94, marking a -0.99% move from the previous day.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Chevron, Medtronic and Danaher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Chevron, Medtronic and Danaher
Top Stock Reports for Microsoft, JPMorgan Chase & Chevron
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), JPMorgan Chase & Co. (JPM) and Chevron Corporation (CVX).